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Nucleotide metabolism enzymes are potential drug targets for treating cancer and autoimmune dis-
eases. Glycinamide ribonucleotide transformylase (GART) is one of the most important trifunc-
tional enzymes involved in purine synthesis. Previous studies have demonstrated the role of
folate inhibitors against tumor activity. In this present study, three components of GART enzyme
were targeted as receptor dataset and in silico analysis was carried out with folate ligand dataset. Toi Journal
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of Biological Sciences (2014), http://dx.doi.oaccomplish the task, Autodock 4.2 was used for determining the docking compatibilities of ligand
and receptor dataset. Taken together, it has been suggested that folate ligands could be potentially
used as inhibitors of GART.
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Nucleotide biosynthesis is an imperative phenomenon in the
synthesis of nucleic acids and metabolic pathways. Nucleotide
biosynthesis follows synergistic pathway involving coordina-
tion between de novo and salvage pathways. Since nucleotides
play a pivotal role in human cells, the enzymes involved in
nucleotide metabolism could be exploited as potential anti-
proliferative drug targets against cancer and autoimmune dis-
eases (Welin et al., 2010). During de novo purine synthesis,
conversion of phosphoribosyl pyrophosphate to inosine mono-
phosphate involves 10 individual steps (Hartman et al., 1959).
However, six different multifunctional enzymes (three mono-
functional, two bifunctional and one trifunctional enzymes)
are engaged in catalysis of above-mentioned steps (Kappock
et al., 2000).
Glycinamide ribonucleotide transformylase (GART) is one
of the most important trifunctional enzymes involved in purine
synthesis. Human GART (HsGART) is composed of three
units: glycinamide ribonucleotide synthetase (GARS), glycin-
amide ribonucleotide transformylase (GARTfase), aminoimi-
dazole ribonucleotide synthetase (AIRS) and all of which
work in a synchronized manner to facilitate purine synthesis.
These three units of human GART (HsGART) catalyze steps
2, 3 and 5 of the de novo purine synthesis pathway. The second
step of purine synthesis is dependent on GARS (N-terminal
enzyme unit) that results in the generation of glycinamide ribo-
nucleotide (GAR), adenosine diphosphate and phosphate ion.
The third step is catalyzed by GARTfase (C-terminal enzyme
unit) resulting in conversion of GAR to N-formylglycinamidehosphate Phosphoribos
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ADP + Pi 
zole ribonucleotide
of the purine de novo bio-s
.
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rg/10.1016/j.sjbs.2014.11.008ribonucleotide using 10-formyltetrahydrofolate as a cofactor.
AIRS (the middle enzymatic domain of HsGART) is impor-
tant for the conversion of formylglycinamidine ribonucleotide
and adenosine triphosphate to aminoimidazole ribonucleotide
(AIR), adenosine diphosphate and phosphate ion (Welin et al.,
2010). This whole process is shown in Fig. 1. The core fourth
step of the purine pathway is performed by phosphoribosyl
formylglycinamidine amidotransferase, encoded by a separate
gene (purL). Interestingly, phosphoribosylamine, the substrate
of GARS, is quite unstable and quickly hydrolyzes to ribose 5-
phosphate within few seconds at physiological temperatures
(Rudolph et al., 1995). Because of its transient nature, phos-
phoribosylamine might be transferred from phosphoribosyl
pyrophosphate amidotransferase to GARS (Wang et al.,
1998).
HsGART gene is localized on chromosome 21 and might
be linked with trisomy disorders (Down syndrome)
(Chadefaux et al., 1984). In addition, elevated serum purine
levels associated with Down’s syndrome may possibly be due
to overexpression of HsGART (Brodsky et al., 1997). In-vivo
studies have suggested that inhibitors of folate-dependent
enzymes play a crucial role in anti-tumor activity. The C-termi-
nal GARTfase domain uses folate cofactor and this has been
associated with anti-tumor activity (Costi and Ferrari, 2001).
The compound (6R)-dideazatetrahydrofolate (lometrexol)
belongs to the class of anti-folates that are speciﬁc inhibitors
of de novo purine synthesis due to potent inhibition of GART
(Bronder and Moran, 2002). A study of the activity of pemetr-
exed (a commercially available chemotherapy drug) against
several recombinant mouse and human enzymes in vitro ledyl Amine Glycinamide ribonucleotide
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Figure 2 2D structures of (a) PY873, (b) PY899 and (c) DIA.
In silico study of GART inhibition by PY873, PY899 and DIA 3to the conclusion that both GART and dihydrofolate reduc-
tase (DHFR) were potential secondary targets for the polyglu-
tamate forms of pemetrexed (Shih et al., 1997; Chattopadhyay
et al., 2006).
Based on these studies, we designed an in silico study
involving docking of three enzyme units of HsGART: GARS,
AIRS and GARTfase against three 2,4-Diamino analogs of
folic acid important for cancer chemotherapy (Sant et al.,
1992). 2,4-Diamino analogs of folic acid have been important
in cancer chemotherapy. Despite its complexity, the underlying
basis of cell growth inhibition by these compounds relies on
their ability to block de novo synthesis of the purine nucleo-
tides, i.e., precursors of DNA (Schoettle et al., 1997). This
work is an extension of our previous study where we reported
inhibition of amido phosphoribosyltransferase using 2,4-Dia-
mino analogs of folic acid (Batool et al., 2013).
2. Materials and methods
2.1. Receptor dataset
Since HsGART is composed of three enzyme units, PDB ids
for its three components were gathered from the literature,
(i) GARS (PDB id: 2QK4) (Welin et al., 2010), (ii) GARTfase
(PDB id: 1ZLY) (Dahms et al., 2005) and (iii) AIRS (PDB id:
2V9Y) (Welin et al., 2010). Binding residue information of
substrate binding for these PDB entries were collected sepa-
rately. 3D structures for the binding sites of GARS and AIRS
were taken from the previous studies (Welin et al., 2010;
Connelly et al., 2013; Zhang et al., 2003). The binding site
interacting residues are shown in Table 1.
2.2. Ligand dataset
The ligand dataset was prepared from three antifolate diamino
inhibitors including (a) 2,4-diamino-6-(3,4,5-trimethoxyben-
zyl)-5,6,7,8-tetrahydro-quinazoline (PY899), (b) 5-((4-carboxy-
4-(4-(((2,4-diaminopyrido[3,2-d]pyrimidine-6-yl)methyl)amino)
benzamido)butyl)carbamoyl) isophthalic acid (DIA), and (c)
2,4-diamino-6-(3,4,5-trimethoxyanilino)-methylpyrido[3,2-d]
pyrimidine (PY873). The structures of PY873, PY899 and DIA
were drawn using Chemofﬁce. Fig. 2 shows the 2D chemical
structures of these ligands.
2.3. Docking studies
Using automated docking program AutoDock4, molecular
docking was performed to monitor possible binding interac-
tions of the three antifolate inhibitors with all three compo-
nents of HsGART (Morris et al., 1998). In brief, polar
hydrogen atoms and Kollman charges were assigned to the
receptor proteins. For ligands, Gasteiger partial charges wereTable 1 Binding site residues for (i) 2QK4, (ii) 1ZLY and (iii) 2V9
No PDB id Substrate binding residue
1 2QK4 Lys148, Val160, Lys162,
2 1ZLY Ile91, Ala140, Glu141, A
3 2V9Y Thr498, Gly499, Gly623,
Please cite this article in press as: Batool, S. et al., In silico analysis of glycinamide ribo
of Biological Sciences (2014), http://dx.doi.org/10.1016/j.sjbs.2014.11.008designated and non-polar hydrogen atoms were merged. All
torsions for ligands were allowed to rotate during docking pro-
cedure. The program AutoGrid was used to generate the grid
maps. Each grid was centered at the structure of the corre-
sponding receptor. The grid dimensions were 80 * 80 * 80 A˚3
with points separated by 0.375 A˚ having random starting posi-
tions, orientations and torsions. The translation, quaternion
and torsion steps were taken from default values indicated in
AutoDock. The Lamarckian genetic algorithm method was
used for minimization using default parameters. The standard
docking protocol for rigid and ﬂexible ligand docking con-
sisted of 100 runs, using an initial population of 150 randomly
placed individuals, with 2.5 · 106 energy evaluations, a maxi-
mum number of 27,000 iterations, a mutation rate of 0.02, a
crossover rate of 0.80 and an elitism value of 1. Cluster analy-
sis using an RMS tolerance of 1.0 A˚ was performed on the
docked results. The binding energy of each cluster is the mean
binding energy of all the conformations present within the
cluster; the cluster with lowest binding energy and higher num-
ber of conformations within it was selected as the docked pose
of that particular ligand.
3. Results
Three components of HsGART were subjected to docking
studies using Autodock 4.2. Binding information pertaining
to these components was gathered and used for a binding anal-
ysis of ligand dataset. Each docked pose was monitored indi-
vidually in order to analyze the binding interactions. Table 2
shows binding energy, intermolecular energy, van der
Waals + hydrogen-bonding + desolvation energies, electro-
static and ﬁnal internal energy, torsional energy and system’s
unbound energies along with inhibition constant values for
the docking studies.
Docking analysis revealed that the ligand dataset showed
interactions with the binding site residues of all the receptors
included in the study. Graphically interactions are shown in
Fig. 3.Y.
s
Glu190, Glu191, Leu192, Leu193, Glu197, Arg220, Asn229, Leu287
sp144, Val143, Leu85
His620, Asn622, Met519, His680, Tyr537, Glu570
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Table 2 Docking Results for (i) glycinamide ribonucleotide synthetase (2QK4), (ii) glycinamide ribonucleotide transformylase
(1ZLY) and (iii) aminoimidazole ribonucleotide synthetase (2V9Y).
PDB IDS 2QK4 1ZLY 2V9Y
Ligand/properties PY873 PY899 DIA PY873 PY899 DIA PY873 PY899 DIA
Binding energy (kcal/mol) 6.03 6.83 5.52 7.06 6.22 5.97 6.57 6.11 5.53
Ki (lM) 37.1 9.85 90.16 6.7 27.54 42.18 15.4 33.43 87.97
Intermolecular energy (kcal/mol) 8.43 8.32 9.99 9.45 7.71 11.34 8.95 7.6 10.9
vdW+Hbond + desolv energy (kcal/mol) 7.53 7.49 7.54 8.9 7.44 8.39 7.66 7.13 7.6
Electrostatic energy (kcal/mol) 0.85 0.83 2.45 0.55 0.27 2.95 1.29 0.47 3.3
Final total internal energy (kcal/mol) 0.77 0.11 164.57 0.2 0.18 0.57 0.86 0.02 1.08
Torsional free energy (kcal/mol) 2.39 1.49 4.47 2.39 1.49 5.37 2.39 1.49 5.37
Unbound system’s energy (kcal/mol) 0.77 0.11 164.57 0.2 0.18 0.57 0.86 0.02 1.08
Temperature (K) 298.5 298.5 298.5 298.5 298.5 298.5 298.5 298.5 298.5
Figure 3 Glycinamide ribonucleotide synthetase (2QK4) interactions with, (a) PY873, (b) PY899, (c) DIA, glycinamide ribonucleotide
transformylase (1ZLY) interactions, (d) PY873, (e) PY899, (f) DIA, (iii) aminoimidazole ribonucleotide synthetase (2V9Y) interactions,
(g) PY873, (h) PY899 and (i) DIA.
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Figure 4 Binding position for 2QK4 Interactions (a) PY873 (b) PY899, (c) DIA, Binding position for 1ZLY Interactions (d) PY873, (e)
PY899, (f) DIA, Binding position for 2V9Y Interactions (g) PY873, (h) PY899 and (i) DIA. Receptors are shown in ribbon while ligands
are shown in sticks.
In silico study of GART inhibition by PY873, PY899 and DIA 53.1. 2QK4 results
The docking results show clearly that PY873, PY899 and DIA
interact to the binding site of GARS. PY873 makes the follow-
ing seven hydrogen bonds: two bonds with Leu193 through its
oxygen atom at a distance of 2.26 and 2.14 A˚ (O. . .H, dis-
tance; 2.26 A˚, 2.12 A˚); third hydrogen bond with Glu190
(O. . .NH, distance; 2.03 A˚); fourth hydrogen bond with
Glu191 (O. . .NH, distance; 2.37); ﬁfth hydrogen bond with
Glu197 (O. . .NH, distance; 2.158 A˚); sixth hydrogen bond
with Arg220 (H. . .O, distance; 2.158 A˚) and a seventh hydro-
gen bond with Asn229 (H. . .O, distance; 2.47 A˚). PY873Please cite this article in press as: Batool, S. et al., In silico analysis of glycinamide ribo
of Biological Sciences (2014), http://dx.doi.org/10.1016/j.sjbs.2014.11.008exhibits hydrophobic interactions with Lys148 and Val160 as
shown in Fig. 3a.
PY899 makes ﬁve of the following hydrogen bonds with the
binding residues: two hydrogen bonds with Glu197 (O. . .H,
distance; 1.9 A˚ and O. . .N, distance; 2.4 A˚); two hydrogen
bonds with Arg220 (–H. . .O, distance; 2.46 A˚ and –H. . .O, dis-
tance; 2.11 A˚) and one hydrogen bond with Glu196 (–O. . .H,
distance; 2.11 A˚). PY899 exhibits hydrophobic interactions
with Asn229, Asp217, Gln216, and Gly195 residues (Fig. 3b).
Fig. 3c shows the binding interactions for DIA which
makes the following eight hydrogen bonds with the binding
residues: Two hydrogen bonds with Glu197 (–O. . .H, distance;nucleotide transformylase inhibition by PY873, PY899 and DIA. Saudi Journal
6 S. Batool et al.2.088 A˚ and –O. . .NH, distance; 1.98 A˚); Two H Bonds with
Gly195 (–O. . .NH, distance; 2.083 A˚ and –O. . .NH, distance;
2.223 A˚); two hydrogen bonds with Lys107 (O. . .NH, dis-
tance; 2.4 A˚ and –O. . .NH, distance; 2.2 A˚); one hydrogen
bond with Leu287 (–H. . .O, distance; 1.8 A˚) and one hydrogen
bond with Val160 (–O. . .NH, distance; 2.3 A˚). DIA exhibits
hydrophobic interactions with Lys148.
3.2. 1ZLY results
PY873 makes the following three hydrogen bonds with the
binding residues: ﬁrst hydrogen bond is observed with
Ala140 (H. . .O, distance; 1.89 A˚); second hydrogen bond with
Glu141 (H. . .O, distance; 2.2 A˚) and the third hydrogen bond
with Asp144 (H. . .O, distance; 1.9 A˚). Hydrophobic interac-
tions are observed with Leu85, Ile91 and Val143 (Fig. 3d).
PY899 makes the following three hydrogen bonds with the
binding residues: First hydrogen bond with Asp144 (H. . .O,
distance; 1.7 A˚) and the other two hydrogen bonds with
Asn106 (H. . .O, distance; 1.98 A˚ and H. . .N, distance;
2.48 A˚). Hydrophobic interactions are noted for Leu85, Ile95
and Val143 residues (Fig. 3e).
DIA makes three hydrogen bonds with Asp144 (H. . .O, dis-
tance; 2 A˚, H. . .O, distance; 2 A˚ and H. . .O, distance; 2 A˚)
while hydrophobic interactions are observed with Leu85,
Ile91, Ala140 and Val143 (Fig. 3f).
3.3. 2V9Y results
PY873 makes four hydrogen bonds with the following binding
residues: (1) Thr498 (O. . .HN, distance; 1.98 A˚); (2) Gly623
(O. . .HN, distance; 1.9 A˚); (3) Asp494 (H. . .O, distance;
1.95 A˚); (4) Asp523 (H. . .O, distance; 2.2 A˚). Hydrophobic
interactions are observed with Lys499, Asn622 and Phe624
(Fig. 3g).
PY899 makes the following six hydrogen bonds: First
hydrogen bond with Asn622 (H. . .O, distance; 2); second
hydrogen bond with Gly623 (HN. . .O, distance; 2 A˚); third
hydrogen bond with Ser625 (HN. . .O, distance;1.86 A˚); fourth
hydrogen bond found with Arg729 (O. . ..H, distance; 2 A˚),
ﬁfth hydrogen bond noticed with Phe624 (HN. . .O, distance;
2.3 A˚) and sixth hydrogen bond seen with Thr730 (O. . .HN,
distance; 2.49 A˚). Hydrophobic interactions are exhibited with
Thr498 (Fig. 3h).
DIA makes the following ﬁve hydrogen bonds: First hydro-
gen bond with Lys629 (H. . .O, distance; 3 A˚); second hydrogen
bond with Glu688 (O. . .H, distance; 2.1 A˚); third hydrogen
bond with Asn622 (H. . .O, distance; 1.9 A˚); fourth
hydrogen bond with Gly623 (H. . .O, distance; 2.03 A˚); ﬁfth
hydrogen bond with Ser625 (H. . .O, distance; 2.6 A˚) while
hydrophobic interactions are seen with Thr498 (Fig. 3i).
Fig. 4 shows binding orientation of the ligands with a bind-
ing pocket of three components of HsGART. This present
study suggests that each of the three ligands binds to the same
binding cavity with its respective receptors.
4. Discussion
This study focuses on the mechanism by which certain antifo-
late inhibitors act against purine synthesis pathways. Previous
studies have demonstrated that methotrexate polyglutamatesPlease cite this article in press as: Batool, S. et al., In silico analysis of glycinamide rib
of Biological Sciences (2014), http://dx.doi.org/10.1016/j.sjbs.2014.11.008retain a potent ability to inhibit DHFR and act as potent
inhibitors of several folate-dependent enzymes, including thy-
midylate synthase and de novo purine synthesis enzymes
(Baram et al., 1988; Allegra et al., 1985a,b; Baggott et al.,
1986). Recent investigations regarding the mechanism of
action of dihydrofolate polyglutamates have indicated that
metabolic inhibition is a multifactorial event that includes
folate substrate depletion and direct inhibition of several crit-
ical folate-dependent enzymes by interaction at multiple intra-
cellular sites (Allegra et al., 1986; Baram et al., 1987; Matherly
et al., 1987).
HsGART consists of three enzyme units: GARS, GARTf-
ase and AIRS. HsGART is involved in catalyzing steps 2, 3
and 5 steps of de novo purine synthesis pathway. In this study,
we analyzed the binding of three DHFR antifolates, PY873,
PY899 and DIA, with human GART. Taken together, our
study reveals that three studied inhibitors demonstrate interac-
tions with the binding residues of receptor dataset along with
favorable energy values. Based on the current study, we pro-
pose GART as a potential target for designing of new speciﬁ-
cally potent and selective antifolate type inhibitors to ﬁnd a
suitable candidate for targeted chemotherapy.Conﬂict of interest
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